Combination therapy with mizoribine for severe childhood IgA nephropathy: A pilot study

Pediatric Nephrology

Volumn 23, Issue 5, 2008, Pages 757-763

  Yoshikawa, Norishige ^a   Nakanishi, Koichi ^a   Ishikura, Kenji ^b   Hataya, Hiroshi ^b   Iijima, Kazumoto ^c   Honda, Masataka ^b  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Clinical trial; Glomerulonephritis; Glomerulosclerosis; Mesangial proliferation; Proteinuria

Indexed keywords

CREATININE; DIPYRIDAMOLE; IMMUNOGLOBULIN A; MIZORIBINE; PREDNISOLONE; WARFARIN;

ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULOSCLEROSIS; GLUCOSURIA; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; KAPLAN MEIER METHOD; LEUKOPENIA; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SODIUM RESTRICTION; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

BIOPSY; CHILD; DIPYRIDAMOLE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, IGA; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY GLOMERULUS; MALE; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PREDNISOLONE; PROSPECTIVE STUDIES; PROTEINURIA; RIBONUCLEOSIDES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 41749084857     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0731-8     Document Type: Article

References (30)

1. Donadio JV, Grande JP (2002) IgA nephropathy. N Engl J Med 347:738-748
2. Alexopoulos E (2004) Treatment of primary IgA nephropathy. Kidney Int 65:341-355
3. Yoshikawa N, Tanaka R, Iijima K (2001) Pathophysiology and treatment of childhood IgA nephropathy. Pediatr Nephrol 16:446-457
4. Yoshikawa N, Ito H, Nakamura H (1992) Prognostic factors in childhood IgA nephropathy. Nephron 60:60-67
5. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura N, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M, Japanese Pediatric IgA Nephropathy Treatment Group (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 10:101-109
6. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H, Japanese Pediatric IgA Nephropathy Treatment Study Group (2006) Steroid treatment for severe childhood IgA nephropathy: A randomized controlled trial. Clin J Am Soc Nephrol 1:511-517
7. Yokota S (2002) Mizoribine: Mode of action and effects in clinical use. Pediatr Int 44:196-198
8. Yoshikawa N, Ito H, Yoshiara S, Nakahara C, Yoshiya K, Hasegawa O, Matsuo T (1987) Clinical course of IgA nephropathy in children. J Pediatr 110:555-560
9. Churg J, Bernstein J, Glassock RJ (1995) Renal disease: Classification and atlas of glomerular diseases, 2nd edn. Igaku-shoin Medical Publishers, Tokyo, Japan, pp 86-88
10. Guignard JP, Santos F (2004) Laboratory investigations. In: Avner ED, Harmon WE, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 399-424
11. Vogt BA, Avner ED (2004) Conditions particularly associated with proteinuria. In: Behrman RE, Kliegman RM, Jenson HB (eds) Nelson textbook of pediatrics, 17th edn. Elsevier Science, Philadelphia, pp 1751-1752
12. Kaiho S, Mizuno K (1985) Sensitive assay systems for the detection of hemoglobin with 2,7-diaminofluorene: Histochemistry and colorimetry for erythrodifferentiation. Anal Biochem 149:117-120
13. Amemiya H, Itoh H (1994) Mizoribine (Bredinin): Mode of action, effects on graft rejection. In: Thomason AW, Starzl TE (eds) Immunosuppressive drugs. Edward Arnold, London, pp 161-176
14. Kamata K, Okubo M, Ishigamori E, Masaki Y, Uchida H, Watanabe K, Kashiwagi N (1983) Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals. Transplantation 35:144-149
15. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S (2000) A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58:317-324
16. Kusumi T, Tsuda M, Katsunuma T, Yamamura M (1989) Dual inhibitory effect of bredinin. Cell Biochem Funct 7:201-204
17. LePage GA, Whitecar JP Jr (1971) Pharmacology of 6-thioguanine in man. Cancer Res 31:1627-1631
18. Barratt J, Feehally J (2006) Treatment of IgA nephropathy. Kidney Int 69:1934-1938
19. Wyatt RJ, Hogg RJ (2001) Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatr Nephrol 16:156-167
20. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA (2004) Immunosuppressive treatments for immunoglobulin A nephropathy: A meta-analysis of randomized controlled trials. Nephrology [Carlton] 9:177-185
21. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353:883-887
22. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157-163
23. Ballardie FW, Roberts IS (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142-148
24. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF (2004) Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842-1849
25. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G (2005) Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 20:2139-2145
26. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68:802-812
27. Nakanishi K, Honda M, Yoshikawa N (2004) Pediatric nephrology around the world: Japan. In Avner ED, Harmon WE, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1491-1493
28. Stevens LA, Greene T, Levey AS (2006) Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 1:874-884
29. Kawasaki Y, Suzuki J, Sakai N, Etoh S, Murai H, Nozawa R, Suzuki H (2004) Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy. Am J Nephrol 24:147-153
30. Nagaoka R, Kaneko K, Ohtomo Y, Yamashiro Y (2002) Mizoribine treatment for childhood IgA nephropathy. Pediatr Int 44:217-223